HSR&D Citation Abstract
Search | Search by Center | Search by Source | Keywords in Title
Impact of medicare part D plan features on use of generic drugs.
Tang Y, Gellad WF, Men A, Donohue JM. Impact of medicare part D plan features on use of generic drugs. Medical care. 2014 Jun 1; 52(6):541-8.
Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs.
To examine the association between Part D plan features and generic medication use.
Data from a 2009 random sample of 1.6 million fee-for-service, Part D enrollees aged 65 years and above, who were not dually eligible or receiving low-income subsidies, were used to examine the association between plan features (generic cost-sharing, difference in brand and generic copay, prior authorization, step therapy) and choice of generic antidepressants, antidiabetics, and statins. Logistic regression models accounting for plan-level clustering were adjusted for sociodemographic and health status.
Generic cost-sharing ranged from $0 to $9 for antidepressants and statins, and from $0 to $8 for antidiabetics (across 5th-95th percentiles). Brand-generic cost-sharing differences were smallest for statins (5th-95th percentiles: $16-$37) and largest for antidepressants ($16-$64) across plans. Beneficiaries with higher generic cost-sharing had lower generic use [adjusted odds ratio (OR) = 0.97, 95% confidence interval (CI), 0.95-0.98 for antidepressants; OR = 0.97, 95% CI, 0.96-0.98 for antidiabetics; OR = 0.94, 95% CI, 0.92-0.95 for statins]. Larger brand-generic cost-sharing differences and prior authorization were significantly associated with greater generic use in all categories. Plans could increase generic use by 5-12 percentage points by reducing generic cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing brand-generic cost-sharing differences from the 25th ($25-$26) to 75th ($32-$33) percentiles, and using prior authorization and step therapy.
Cost-sharing features and utilization management tools were significantly associated with generic use in 3 commonly used medication categories.